Australia markets open in 3 hours 25 minutes

Cytokinetics, Incorporated (CYTK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
64.80-2.02 (-3.02%)
At close: 04:00PM EDT
64.80 0.00 (0.00%)
After hours: 04:20PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 6.99B
Enterprise value 7.13B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)856.54
Price/book (mrq)N/A
Enterprise value/revenue 946.71
Enterprise value/EBITDA -15.61

Trading information

Stock price history

Beta (5Y monthly) 0.68
52-week change 376.49%
S&P500 52-week change 322.64%
52-week high 3110.25
52-week low 325.98
50-day moving average 370.54
200-day moving average 350.95

Share statistics

Avg vol (3-month) 32.05M
Avg vol (10-day) 31.12M
Shares outstanding 5104.58M
Implied shares outstanding 6104.58M
Float 8102.33M
% held by insiders 10.57%
% held by institutions 1112.57%
Shares short (15 Apr 2024) 414.04M
Short ratio (15 Apr 2024) 45.79
Short % of float (15 Apr 2024) 421.97%
Short % of shares outstanding (15 Apr 2024) 413.43%
Shares short (prior month 15 Mar 2024) 414.8M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:6
Last split date 325 June 2013

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-7,620.69%

Management effectiveness

Return on assets (ttm)-33.73%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)7.53M
Revenue per share (ttm)0.08
Quarterly revenue growth (yoy)-14.60%
Gross profit (ttm)N/A
EBITDA -484.31M
Net income avi to common (ttm)-526.24M
Diluted EPS (ttm)-5.45
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)614.82M
Total cash per share (mrq)5.97
Total debt (mrq)756.91M
Total debt/equity (mrq)N/A
Current ratio (mrq)6.12
Book value per share (mrq)-3.80

Cash flow statement

Operating cash flow (ttm)-414.33M
Levered free cash flow (ttm)-261.36M